Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Considerations in the Treatment of Hormone Receptor–Positive Breast Cancer: A 2008 Perspective

Release Date: September 25, 2008| Expiration Date: September 25, 2009
Sep 6, 2008, Washington, DC

Lecture Overview

Clinical implications for these patients will be the focus of this activity, which will utilize a format that will provide the user with the ability to apply this information to defined clinical situations. This educational program is directed toward medical, surgical, and radiation oncologists with an interest in the treatment of breast cancer. Physician assistants, research nurses, and fellows with an interest in the treatment of breast cancer are also invited to participate.

At the conclusion of this activity, you should be able to:

  • Review current applications of aromatase inhibitors within various clinical settings, including patients with newly diagnosed disease, patients currently receiving tamoxifen, and patients who have completed tamoxifen within selected time frames
  • Compare the safety and efficacy of the various aromatase inhibitors within selected clinical contexts
  • Discuss potential mechanisms of resistance to aromatase inhibitors and the rationale for combining aromatase inhibitors with targeted agents to circumvent resistance and/or enhance efficacy
  • Enumerate options for the maintenance of bone health in patients undergoing aromatase inhibitor or other adjuvant therapy as well as in those with metastatic disease
  • Discuss the incidence and clinical relevance of and amelioration strategies for the adverse events associated with therapeutic agents designed to maintain bone health in women with breast cancer

Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. Complete the pre-test.
  3. View and study all Flash video presentations.
  4. Complete the CME test.
  5. Answer the evaluation questions.
  • CME credit will be granted for online participation only.

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians' Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from Considerations in the Treatment of Hormone Receptor–Positive Breast Cancer: A 2008 Perspective symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Angela Brodie, PhD
Remuneration – Novartis Pharmaceuticals Corporation

Julie R. Gralow, MD
Research Funding – Amgen, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals

Nicholas Robert, MD
Paid Consultant/Advisory Board Member – Amgen, AstraZeneca, Britol-Myers Squibb Company, and Novartis Pharmaceuticals Corporation
Speaker’s Bureau – Abraxis Oncology, AstraZeneca, GlaxoSmithKline, Novartis Pharmaceuticals Corporation
Research Funding – Abraxis Oncology, Eli Lilly and Company, Pfizer Inc., and sanofi-aventis U.S.

Hope S. Rugo, MD
Speaker’s Bureau – AstraZeneca and Genomic Health, Inc.
Research Funding – Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc., and Roche Pharmaceuticals

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians' Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians' Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Considerations in the Treatment of Hormone Receptor–Positive Breast Cancer: A 2008 Perspective
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3456
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com

Educational Grants

An educational grant for this activity was provided by:


  1. Novartis Oncology